Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Praxis Precision Medicines (NASDAQ: PRAX) will report first quarter 2026 financial results and provide a corporate update before markets open on Thursday, May 7, 2026 at 8:30 am ET.
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) will report first quarter 2026 financial results and provide a corporate update before markets open on Thursday, May 7, 2026 at 8:30 am ET. The company will host a conference call and live webcast; registration and replay links are available on the investor website.
Praxis will also present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026 at 7:20 pm EDT, with a live webcast and a replay available for approximately 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PRAX
On May 5, the first trading day after this news, PRAX closed 1.28% below the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- Q1 2026 period end
- March 31, 2026
- Quarter for upcoming financial results
- Earnings release date
- May 7, 2026
- Q1 2026 results and corporate update before market open
- Earnings call time
- 8:30 am ET
- Start time for Q1 2026 conference call and webcast
- Conference presentation date
- May 12, 2026
- Bank of America Securities Health Care Conference presentation
- Conference presentation time
- 7:20 pm EDT (4:20 pm PDT)
- Scheduled time at Encore at the Wynn Hotel
- Webcast replay window
- approximately 90 days
- Duration replay will be available after conference presentation
Previous Conferences,earnings date Reports
-
Set reporting date for FY 2025 results and outlined multiple conference appearances.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
central nervous system medical
cns medical
biopharmaceutical medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026.
The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
In addition, Praxis will be attending and presenting at the Bank of America Securities Health Care Conference. A corporate presentation will take place on Tuesday, May 12, 2026, at 7:20 pm EDT (4:20 pm PDT) at the Encore at the Wynn Hotel in Las Vegas, NV. A live webcast of the presentation will be available here. A replay of the webcast will be available after the event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.